{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:18:42Z","timestamp":1790993922925,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009712","name":"Dravet Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012739","name":"Zogenix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013631","name":"Montana Water Center, Montana State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.yebeh.2021.108024","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T08:47:42Z","timestamp":1621500462000},"page":"108024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"PA","title":["Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome"],"prefix":"10.1016","volume":"121","author":[{"given":"Kim I.","family":"Bishop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Isquith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A.","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-2862","authenticated-orcid":false,"given":"Arnold R.","family":"Gammaitoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Farfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Wirrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-7312","authenticated-orcid":false,"given":"Tilman","family":"Polster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108024_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108024_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/epi.12652","article-title":"Dravet syndrome\u2014from epileptic encephalopathy to channelopathy","volume":"55","author":"Brunklaus","year":"2014","journal-title":"Epilepsia"},{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108024_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1528-1167.2006.00688.x","article-title":"Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings","volume":"47","author":"Wolff","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0035","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/epi.12927","article-title":"The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009","volume":"56","author":"Bayat","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0040","doi-asserted-by":"crossref","unstructured":"Bender AC, Morse RP, Scott RC, Holmes GL, Lenck-Santini PP. SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome. Epilepsy Behav 2012;23:177-86.","DOI":"10.1016\/j.yebeh.2011.11.022"},{"issue":"pt 8","key":"10.1016\/j.yebeh.2021.108024_b0045","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","article-title":"Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome","volume":"135","author":"Brunklaus","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2021.108024_b0050","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/320609","article-title":"De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy","volume":"68","author":"Claes","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108024_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1528-1167.2011.02997.x","article-title":"The genetics of Dravet syndrome","volume":"52","author":"Marini","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12319","article-title":"Seizure burden in severe early-life epilepsy: perspectives from parents","volume":"4","author":"Berg","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2021.108024_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eplepsyres.2011.03.005","article-title":"Neuropsychological development in children with Dravet syndrome","volume":"95","author":"Chieffo","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108024_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107079","article-title":"Intellectual functioning and behavior in Dravet syndrome: a systematic review","volume":"108","author":"Jansson","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108024_b0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.braindev.2015.12.014","article-title":"Cognitive-behavioral profiles in teenagers with Dravet syndrome","volume":"38","author":"Olivieri","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2021.108024_b0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dmcn.12709","article-title":"Dravet syndrome in Sweden: a population-based study","volume":"57","author":"Rosander","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/jmg.2008.062323","article-title":"Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients","volume":"46","author":"Depienne","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.yebeh.2021.108024_b0090","article-title":"Epileptic encephalopathies: an overview","volume":"2012","author":"Khan","year":"2012","journal-title":"Epilepsy Res Treat"},{"key":"10.1016\/j.yebeh.2021.108024_b0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108024_b0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/epi4.12281","article-title":"Autism spectrum disorder and cognitive profile in children with Dravet syndrome: delineation of a specific phenotype","volume":"4","author":"Ouss","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2021.108024_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","article-title":"Cognitive effects of antiepileptic drugs","volume":"4","author":"Park","year":"2008","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0115","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/epi.14589","article-title":"Cognitive outcomes following epilepsy in infancy: a longitudinal community-based study","volume":"59","author":"O'Reilly","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/09297049.2014.959480","article-title":"Cognitive characterization of children with Dravet syndrome: a neurodevelopmental perspective","volume":"21","author":"Acha","year":"2015","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12160-009-9097-4","article-title":"Executive functioning: overview, assessment, and research issues for non-neuropsychologists","volume":"37","author":"Suchy","year":"2009","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.yebeh.2021.108024_b0130","series-title":"BRIEF\u00ae2: Behavior Rating Inventory of Executive Function\u00ae","author":"Gioia","year":"2015"},{"key":"10.1016\/j.yebeh.2021.108024_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.acn.2007.08.010","article-title":"Assessment of executive functions: review of instruments and identification of critical issues","volume":"23","author":"Chan","year":"2008","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0140","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s10826-018-1079-3","article-title":"Executive function and emotional, behavioral, and social competence problems in children with epilepsy","volume":"27","author":"Healy","year":"2018","journal-title":"J Child Fam Stud"},{"key":"10.1016\/j.yebeh.2021.108024_b0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/B978-0-444-52891-9.00073-7","article-title":"Cognitive side-effects of antiepileptic drugs in children","volume":"111","author":"Ijff","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.seizure.2006.02.013","article-title":"Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy","volume":"15","author":"Lagae","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108024_b0155","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/01.WNL.0000115653.82763.07","article-title":"Cognitive side effects of antiepileptic drugs in children","volume":"62","author":"Loring","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108024_b0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/epi4.12413","article-title":"A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway","volume":"5","author":"Heger","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2021.108024_b0165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108024_b0170","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40263-019-00666-8","article-title":"Recent advances in the drug treatment of Dravet syndrome","volume":"33","author":"Wirrell","year":"2019","journal-title":"CNS Drugs"},{"issue":"suppl 3","key":"10.1016\/j.yebeh.2021.108024_b0175","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/cjn.2016.243","article-title":"Dravet syndrome: diagnosis and long-term course","volume":"43","author":"Connolly","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2021.108024_b0180","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yebeh.2021.108024_b0185","unstructured":"Bishop KI, Isquith PK, Gioia G, Morrison G, Gammaitoni AR, Haney D, et al. Profound reduction in seizure frequency (\u226575%) leads to improved everyday executive function: analysis from a phase 3 study of ZX008 (fenfluramine HCL) in children\/young adults with Dravet syndrome [abstract]. American Epilepsy Society Annual Meeting; December 6-10, 2019; Baltimore, MD."},{"key":"10.1016\/j.yebeh.2021.108024_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1076\/chin.6.3.235.3152","article-title":"TEST REVIEW: behavior rating inventory of executive function","volume":"6","author":"Gioia","year":"2000","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0195","unstructured":"Lagae L, Sullivan J, Nabbout R, Pringsheim M, Farfel G, Galer BS, et al. Fintepla\u00ae (fenfluramine HCl oral solution) provides long-term clinically meaningful reduction in seizure frequency: results of an open-label extension study [poster]. American Epilepsy Society Annual Meeting; November 30\u2013December 4, 2018; New Orleans, LA."},{"key":"10.1016\/j.yebeh.2021.108024_b0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/09297049.2018.1424326","article-title":"Everyday executive function in focal onset pediatric epilepsy on the parent-report BRIEF2","volume":"25","author":"Black","year":"2018","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0205","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1037\/0033-2909.131.4.483","article-title":"Informant discrepancies in the assessment of childhood psychopathology: a critical review, theoretical framework, and recommendations for further study","volume":"131","author":"De Los Reyes","year":"2005","journal-title":"Psychol Bull"},{"key":"10.1016\/j.yebeh.2021.108024_b0210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/arclin\/16.2.183","article-title":"Interpreting change on the WAIS-III\/WMS-III in clinical samples","volume":"16","author":"Iverson","year":"2001","journal-title":"Arch Clin Neuropsychol"},{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108024_b0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1528-1167.2011.03000.x","article-title":"Cognitive development in children with Dravet syndrome","volume":"52","author":"Ragona","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0220","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1528-1167.2010.02925.x","article-title":"Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients","volume":"52","author":"Ragona","year":"2011","journal-title":"Epilepsia"},{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108024_b0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1167.2011.02999.x","article-title":"Cognitive and behavioral characteristics of children with Dravet syndrome: an overview","volume":"52","author":"Guzzetta","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/S0012162206000454","article-title":"Psychosocial problems and seizure-related factors in children with epilepsy","volume":"48","author":"Hoie","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0235","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yebeh.2019.04.003","article-title":"Evaluating the mediating role of executive functions for antiepileptic drugs' effects on IQ in children and adolescents with epilepsy","volume":"96","author":"Helmstaedter","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108024_b0240","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.yebeh.2015.10.027","article-title":"Disorders of early language development in Dravet syndrome","volume":"54","author":"Chieffo","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108024_b0245","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0250","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13760-019-01090-x","article-title":"Impact of epilepsy duration, seizure control and EEG abnormalities on cognitive impairment in drug-resistant epilepsy patients","volume":"119","author":"Gavrilovic","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2021.108024_b0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0079-6123(02)35037-4","article-title":"Progressive cognitive decline in adolescents and adults with epilepsy","volume":"135","author":"Dodrill","year":"2002","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.yebeh.2021.108024_b0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1528-1157.1981.tb04334.x","article-title":"Changes in seizure frequency and test-retest scores on the Wechsler Adult Intelligence Scale","volume":"22","author":"Seidenberg","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"16","key":"10.1016\/j.yebeh.2021.108024_b0270","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1017\/S0033291719002836","article-title":"A role for 5-HT4 receptors in human learning and memory","volume":"50","author":"Murphy","year":"2020","journal-title":"Psychol Med"},{"key":"10.1016\/j.yebeh.2021.108024_b0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fphar.2017.00191","article-title":"Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish","volume":"8","author":"Sourbron","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108024_b0280","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/21622965.2013.748389","article-title":"Contribution of rating scales to the assessment of executive functions","volume":"2","author":"Isquith","year":"2013","journal-title":"Appl Neuropsychol Child"},{"key":"10.1016\/j.yebeh.2021.108024_b0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","article-title":"Clinical significance: a statistical approach to defining meaningful change in psychotherapy research","volume":"59","author":"Jacobson","year":"1991","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1528-1157.1998.tb01379.x","article-title":"Does presurgical IQ predict seizure outcome after temporal lobectomy? Evidence from the Bozeman Epilepsy Consortium","volume":"39","author":"Chelune","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0295","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1046\/j.1528-1157.2002.23602.x","article-title":"Determining reliable cognitive change after epilepsy surgery: development of reliable change indices and standardized regression-based change norms for the WMS-III and WAIS-III","volume":"43","author":"Martin","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108024_b0300","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.yebeh.2021.108024_b0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1355617710000093","article-title":"Is the behavior rating inventory of executive function more strongly associated with measures of impairment or executive function?","volume":"16","author":"McAuley","year":"2010","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.yebeh.2021.108024_b0310","first-page":"404","article-title":"Assessment of executive functioning in childhood epilepsy: the Tower of London and BRIEF","volume":"18","author":"MacAllister","year":"2012","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2021.108024_b0315","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1469-8749.2007.00412.x","article-title":"Executive functioning in childhood epilepsy: parent-report and cognitive assessment","volume":"49","author":"Parrish","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108024_b0320","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:44:29Z","timestamp":1761504269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":64,"alternative-id":["S1525505021002584"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108024","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108024"}}